Log in

1093 CSPC Pharmaceutical Group Limited HKEX · China

CSPC Pharmaceutical Group (1093) news

CSPC Pharmaceutical Group Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 1093, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest CSPC Pharmaceutical Group news

We have not published a story on CSPC Pharmaceutical Group yet. When there is news, it will appear here.

Questions about CSPC Pharmaceutical Group

What is the ticker symbol of CSPC Pharmaceutical Group?

CSPC Pharmaceutical Group Limited trades under the ticker 1093 on HKEX.

Where is CSPC Pharmaceutical Group listed?

CSPC Pharmaceutical Group Limited is listed on HKEX. Our directory also records these other listings: GETTEX:CVG; LS:548183; LSX:548183; OTC:CSPCY.

Which country or territory is CSPC Pharmaceutical Group listed under?

Our directory records CSPC Pharmaceutical Group Limited under China.

What does CSPC Pharmaceutical Group do?

Our directory classifies CSPC Pharmaceutical Group Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of CSPC Pharmaceutical Group?

The ISIN recorded for CSPC Pharmaceutical Group Limited is HK1093012172.

Does aibio.space cover CSPC Pharmaceutical Group?

aibio.space lists CSPC Pharmaceutical Group Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to CSPC Pharmaceutical Group?

Companies in our directory listed in the same country and business area as CSPC Pharmaceutical Group: Chongqing Zhifei Biological Products Co., Beijing Luzhu Biotechnology Co., JW (Cayman) Therapeutics Co., Fujian Haixi Pharmaceuticals Co., Hvsen Biotechnology Co., XtalPi Holdings.

Investor discussion: CSPC Pharmaceutical Group

Members talk about CSPC Pharmaceutical Group (1093). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at CSPC Pharmaceutical Group, newest first. Each line links the filing it comes from.

  1. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION - ENTERING INTO OF (1) FX SWAP CONTRACT AND (2) FX FORWARD CONTRACTS. Source

  2. Mergers

    Transaction under the Listing Rules: FURTHER ANNOUNCEMENT - UPDATE ON DISCLOSEABLE TRANSACTION IN RELATION TO THE PROPOSED H SHARE LISTING OF CSPC INNOVATION. Source

  3. Financings

    Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES, RE-ELECTION OF RETIRING DIRECTORS, ADOPTION OF NEW ARTICLES OF ASSOCIATION, ADOPTION OF NEW SHARE OPTION SCHEME AND NOTICE OF ANNUAL GENERAL MEETING. Source

  4. Mergers

    Transaction under the Listing Rules: FURTHER ANNOUNCEMENT - UPDATE ON DISCLOSEABLE TRANSACTION IN RELATION TO THE PROPOSED H SHARE LISTING OF CSPC INNOVATION. Source

  5. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION - DEEMED DISPOSAL OF EQUITY INTEREST IN CSPC INNOVATION ARISING FROM THE PROPOSED LISTING OF THE H SHARES OF CSPC INNOVATION. Source

  6. Financings

    Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES, MANDATE TO GRANT OPTIONS AND RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of CSPC Pharmaceutical Group's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE III CLINICAL STUDY OF ANBENITAMAB IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE FIRST-LINE TREATMENT OF HER2-POSITIVE ADVANCED BREAST CANCER PRESENTED AS A PROFFERED PAPER PRESENTATION AT THE ESMO CONGRESS 2026 AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - UPDATED OVERALL SURVIVAL (OS) RESULTS FROM A PHASE III CLINICAL STUDY OF ANBENITAMAB FOR THE TREATMENT OF HER2-POSITIVE ADVANCED GASTRIC CANCER/GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA PRESENTED AS A RAPID ORAL PRESENTATION AT THE ESMO CONGRESS 2026

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - BATOCLIMAB INJECTION (SUBCUTANEOUS INJECTION) OBTAINS DRUG REGISTRATION CERTIFICATE FROM THE NMPA

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE FIRST-LINE TREATMENT OF UNRESECTABLE RECURRENT OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER OFFICIALLY INITIATED IN CHINA

  5. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2066 FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION OFFICIALLY INITIATED IN CHINA

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYH2083 EYE DROPS FOR THE TREATMENT OF DRY EYE DISEASE OFFICIALLY INITIATED IN CHINA

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2018 SHARE AWARD SCHEME

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT - SYS6088 INJECTION (A TRI-SPECIFIC ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT - SYS6062 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL STUDY OF SYS6002 AS MONOTHERAPY FOR THE TREATMENT OF ADVANCED CERVICAL CANCER PRESENTED AS A RAPID ORAL PRESENTATION AT THE 2026 ANNUAL GLOBAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY (IGCS 2026)

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT - LATEST UPDATES FROM 8 CLINICAL TRIALS TO BE PRESENTED AT THE ESMO CONGRESS 2026

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL STUDY OF EFMEDAGLUTIDE ALFA INJECTION IN COMBINATION WITH METFORMIN IN CHINESE ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS PRESENTED IN A SHORT ORAL DISCUSSION AT THE 62ND ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD 2026)

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PHASE IB CLINICAL TRIAL OF JMT206 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OVERWEIGHT OR OBESITY OFFICIALLY INITIATED AT THE FIRST STUDY CENTRE IN CHINA

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT - RECOMBINANT HERPES ZOSTER VACCINE (SYS6052) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT - SYS6077 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

  17. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF BECOTATUG (JMT101) IN COMBINATION WITH OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NSCLC HARBOURING EGFR EXON 20 INSERTION MUTATIONS ACHIEVES POSITIVE TOPLINE RESULTS

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE TREATMENT OF ADVANCED BREAST CANCER OFFICIALLY INITIATED IN CHINA

  19. HKEXnews

    NOTIFICATION LETTER TO NON-REGISTERED HOLDER AND REQUEST FORM

  20. HKEXnews

    NOTIFICATION LETTER TO SHAREHOLDER AND CHANGE REQUEST FORM

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1093 on TradingView.

Listing details

CSPC Pharmaceutical Group Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 1093, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
CSPC Pharmaceutical Group Limited
Ticker
1093
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
HK1093012172
Other listed symbols
GETTEX:CVG; LS:548183; LSX:548183; OTC:CSPCY
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.